Delivery Order SPE2DB24D3013-SPE2DB25FFPAK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,483.62 to AmerisourceBergen Drug Corp for RYTARY ER 23.75 mg-95 mg capsules (100-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitively awarded transaction. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,013.49 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 36.25 MG-145 MG capsules (100-count) under a firm fixed-price contract. The award was made on September 15, 2025, with an ultimate completion date of September 16, 2025, and does not include a set-aside designation. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.55 to AmerisourceBergen Drug Corp for RYTARY ER 36.25 mg-145 mg capsules (100-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of April 24, 2025, and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,989.57 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count packages). This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive award under DLA's existing supply chain framework. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,910.55 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg-195 mg capsules (100-count), a Parkinson's disease medication. This firm fixed-price delivery order, issued on September 16, 2025, with an ultimate completion date of September 17, 2025, was awarded competitively without a set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a delivery order valued at $6,241.31 to AmerisourceBergen Drug Corp for Rytary ER 36.25 mg–145 mg capsules (100-count supply) on June 5, 2025, with completion scheduled for June 6, 2025. This non-set-aside, firm fixed-price delivery order represents pharmaceutical procurement for military healthcare support. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement and holds...
- The Defense Logistics Agency awarded a delivery order valued at $2,102.87 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg–195 mg capsules (100 count) on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $13,679.70 to AmerisourceBergen Drug Corp for the supply of Rytary ER 36.25 mg-145 mg capsules (100 count) under a firm fixed price contract. This competitive award, issued on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $1,826.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RYTARY ER (extended-release carbidopa/levodopa) 36.25 mg-145 mg capsules, 100-count bottles. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 8, 2025. AmerisourceBergen will fulfill this pharmaceutical supply requirement from its corporate office location in Conshohocken, Pennsylvania, where the company serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $6.7K to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg-195 mg capsules (100-count units). This non-set-aside, firm fixed-price delivery order was executed on August 6, 2025, with an ultimate completion date of August 7, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RYTARY is a combination levodopa/carbidopa extended-release medication used in the treatment of...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPAKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,935.59 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The delivery order operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026. This delivery order supports the Department of Defense's pharmaceutical supply chain requirements through AmerisourceBergen's established relationship with the DLA Medical Supply Chain. RYTARY is a medication used in the treatment of Parkinson's disease, reflecting the pharmaceutical distributor's role in supplying specialized neurological treatments to military healthcare systems. The award demonstrates AmerisourceBergen's continued capability to meet federal medical procurement needs through competitive processes and its position as a critical vendor for military and veteran healthcare programs. The DLA is currently planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards, positioning firms like AmerisourceBergen to continue supporting global military medical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 8/5/25 |